---
title: "Return on Investment: Open-source Adoption"
author: "James Black & Orla Doyle ![](logos/novartis-logo.webp){height=30px style=\"vertical-align: middle;\"}, Ning Leng ![](logos/roche-logo.png){height=30px style=\"vertical-align: middle;\"}, Phil Bowsher ![](logos/posit-logo.png){height=30px style=\"vertical-align: middle;\"}"
date: 2025-09-15
format:
  revealjs:
    logo: ""
    footer: "OS ROI | R/Pharma Summit | Atlanta 2025"
    slide-number: true
    chalkboard: true
    multiplex: false
    preview-links: auto
    code-fold: false
    code-tools: true
    code-line-numbers: true
    scrollable: true
    incremental: false
    transition: slide
    background-transition: fade
    highlight-style: github
execute:
  echo: true
  warning: false
  message: false
  freeze: auto
---

## Welcome

![](images/roi_meme.jpeg)

## ROI for open-source adoption

Why is ROI an important conversation for open-source adoption?

- We work in a high stakes yet risk averse industry. 

- Value and impact of open-source is sometimes misunderstood. 

- To acquire and / or sustain investment, business critical framing is often needed. 

## Adoption and ROI on the Rise{.smaller}

::: {.columns}
::: {.column width="50%"}
Ross Farugia, pharmaverse^[https://phuse.s3.eu-central-1.amazonaws.com/Archive/2024/Connect/EU/Strasbourg/PRE_OS01.pdf]
![](images/r_trajectory.png)

Vincent Chen, Roche^[https://insightsengineering.github.io/nest-2023-summeR/resources/NEST_%20Now%20&%20Future.pdf]
![](images/nest_roche.png)
:::
::: {.column width="50%"}
Nick Masel, JnJ at posit conf 2024^[https://nicholas-masel.github.io/posit2024/2024_posit_conf.html#/benefits-of-shift-to-shiny]
![](images/nick_m_shiny.png)
James Black at R/Pharma 2024^[https://www.youtube.com/watch?v=TMZNcuvJS-0]
![](images/james_b_roi.png)
:::
::: 




## Proposal

::: {.callout}
# Whitepaper for ROI
We suggest collaborating on a white paper to consolidate fragmented knowledge on ROI for open-source adoption in clinical trialsâ€”creating a shared evidence base for the entire industry.

If you would like to be involved please email: phil@posit.co, james_alexander.black@novartis.com, orla.doyle@novartis.com, 
:::

## On the shoulders of *colleagues*

- The [PHUSE whitepaper on OS](https://phuse-org.github.io/E2E-OS-Guidance/why.html) includes notes on the 'why'
- The [PHUSE effort to discuss OS](https://phuse-org.github.io/OSTCDA/cost.html) currently has a gap in community engagement
- Numerous talks exist. [Check out Phil's notes](https://github.com/rinpharma/whitepaper_ROI/blob/main/phils_ROI_Outline.md).
 

## Let's hear from you


```{=html}
<iframe src="https://wall.sli.do/event/o6TeNbYp7uz7ebWMJZSZmL/?section=3639324c-aa9d-4b7d-9d56-e7e10389ad5b"
        style="width:100%; height:500px; border:none;"
        allowfullscreen
        data-external="1"></iframe>
```

## Wrap up

- How might this type of paper help you? 
- Roundtables - let's continue discussions on ROI
- Volunteers to contribute to the ROI Whitepaper 
